Money Makers Mentor

Nestle Acquires FDA Approved Peanut Allergy Treatment Maker, Aimmune Therapeutics

This week, Nestle Health Services (NHSc), a subsidiary of food and beverage company Nestle, announced that it has acquired bio-pharmaceutical Aimmune Therapeutics for an estimated $2.6 billion.  

Nestle estimates that up to 240 million people worldwide suffer from food allergies, with peanut allergy being the most common. The CEO of NHSc, Greg Behar said that Aimmune has potential sales of $1 billion and that the deal is expected to add to cash earnings by 2022/2023. The deal is expected to close in the fourth quarter of this year.

“This transaction brings together Nestlé’s nutritional science leadership with one of the most innovative companies in food allergy treatment. Together we will be able to offer a wide range of solutions that can transform the lives of people sufferin…

Leave A Reply

Your email address will not be published.